Within this animation the concept of bioorthogonal imaging involving a clearing agent is visualized. First, a TCO tagged antibody is administered and allowed for sufficient time to accumulate in target tissue. Excess antibody still in circulation is inactivated and excreted by a polymeric clearing agent. A 18F labeled tetrazine is then given, and ligates to the pre-accumulated antibody within a short time span by the tetrazine-TCO bioorthogonal ligation. Non-bound 18F-tetrazine imaging agent is rapidly excreted via the kidneys, allowing for PET imaging with high contrast.
This project has received funding from the European Union's EU Framework Programme for Research and Innovation Horizon 2020 under Grant Agreement no. 668532